ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

ENDONOVO THERAPEUTICS, INC.

Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023

$0.00+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $135.08K
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Sep 30, 2023

Endonovo Therapeutics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Endonovo Therapeutics's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Endonovo Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-1000 reverse split on Dec 20, 2019
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ENDV.

Revenue growth1699.9% · median 23.9%

Gross margin96.2% · median 80.4%

Operating margin-1023.2% · median -21.4%

Net margin-1722.2% · median -26.7%

Company	Revenue	Growth
LIVN	$1.47B	+12.4%
AXGN	$251.17M	+23.6%
ECOR	$36.97M	+33.5%
ENDV	$255.72K	+1699.9%
NXL	$217.16K	+24.2%
FOCL	–	–

Company

Exchange: OTC
Industry: Electromedical & Electrotherapeutic Apparatus
Fiscal year ends: December 31
Employees: 1
Held by institutions: 0.0%
Auditor: Rose, Snyder & Jacobs LLP
SEC CIK: 1528172

Advertisement
300 × 250